The US Food and Drug Administration (FDA) has approved United States-based Pfizer's Lorbrena (lorlatinib) for earlier -treated ALK-positive metastatic non-small cell lung cancer (NSLC), it was reported yesterday.
The product is a third-generation anaplastic lymphoma kinase tyrosine kinase inhibitor intended to treat patients with ALK-positive metastatic NSLC whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.
The product was approved based on results of a non-randomised, dose-ranging and activity-estimating, multi-cohort and multicentre phase 1/2 study.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT